# 2011

## SUMMARY REPORT

On

#### Antimicrobials Sold or Distributed for Use in Food-Producing Animals





Food and Drug Administration Department of Health and Human Services Section 105 of the Animal Drug User Fee Amendments of 2008 (ADUFA) (110 P.L. 316; 122 Stat. 3509) amended section 512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b) to require that sponsors of applications for new animal drugs containing an antimicrobial active ingredient submit an annual report to the Food and Drug Administration on the amount of each such ingredient in the drug that is sold or distributed for use in food-producing animals, including information on any distributor-labeled product. This legislation was enacted to assist FDA in its continuing analysis of the interactions (including drug resistance), efficacy, and safety of antibiotics approved for use in both humans and food-producing animals (H. Rpt. 110-804).

Each report submitted to the FDA must specify: (1) the amount of each antimicrobial active ingredient by container size, strength, and dosage form; (2) quantities distributed domestically and quantities exported; and (3) a listing of the target animals, indications, and production classes that are specified on the approved label of the product. Sponsors of antimicrobial drug products that are approved and labeled for more than one food-producing animal species are not required to report sales and distribution information for each individual animal species. Only total product sales information is required. Each year's report provides monthly sales and distribution data for the preceding calendar year. These reports are separate from periodic drug experience reports that are required under 21 CFR 514.80(b)(4).

Section 105 of ADUFA also directs the FDA to make annual summaries of the reported information publicly available. In accordance with statutory requirements designed to protect confidential business information, annual sales and distribution data are summarized by drug class and only those antimicrobial classes with three or more distinct sponsors of approved and actively marketed animal drug products are independently reported. Antimicrobial classes with fewer than three distinct sponsors are reported collectively as "Not Independently Reported" (NIR) if the product was marketed domestically or "Not Independently Reported Export" (NIRE) if the product was exported. The number of distinct sponsors in a particular antimicrobial class is determined by two criteria: (1) the sponsor must be named in 21 CFR 510.600 as the holder of an approved application for an animal drug product in that particular class on the last day of the annual reporting period, and (2) the sponsor must have actively sold or distributed such animal drug product at some point during that annual reporting period.

FDA's annual summary report for 2011 is presented in Table 1. The annual totals provided in Table 1 reflect all approved uses of all dosage forms (e.g., injectable, oral, medicated feed) of the identified classes of actively marketed drugs in food-producing animals. Table 2 lists the 17 antimicrobial drug classes represented in the report. As reference, this table also lists the specific drugs in each class for which there were actively marketed animal drug products. This summary report includes antimicrobial drugs that are specifically approved for antibacterial uses or are known to have antibacterial properties. Some antimicrobial drug products are approved and labeled for use in multiple species, including both food- and nonfood-producing animals, such as dogs and horses. For these products, sales and distribution data was not required to be reported to FDA by species.

Anti-fungal and anti-viral drugs are not included in this report because, with the exception of formalin and hydrogen peroxide water immersion products, there are currently no approved drug products actively marketed for these purposes in food-producing animals.

#### Table 1. Antimicrobial Drugs Approved for Use in Food-Producing Animals:2011 Sales and Distribution Data Reported by Drug Class

	Antimicrobial Class	Annual Totals (kg <sup>1</sup> )
Domestic	Aminoglycosides	214,895
	Cephalosporins <sup>2</sup>	26,611
	Ionophores	4,123,259
	Lincosamides <sup>2</sup>	190,101
	Macrolides	582,836
	Penicillins <sup>2</sup>	880,163
	Sulfas <sup>2</sup>	371,020
	Tetracyclines <sup>2</sup>	5,642,573
	NIR <sup>2, 3</sup>	1,510,572
Export <sup>4</sup>	Tetracyclines <sup>2</sup>	15,321
	NIRE <sup>2,5</sup>	185,333

<sup>4</sup> Only includes exports of FDA-approved, US-labeled antimicrobial drugs approved for use in food-producing animals.

<sup>5</sup> NIRE = Not Independently Reported Export. Antimicrobial classes for which there were less than three distinct sponsors exporting products were not independently reported. These classes include: Aminocoumarins, Aminoglycosides, Amphenicols, Cephalosporins, Diaminopyrimidines, Fluoroquinolones, Glycolipids, Ionophores, Lincosamides, Macrolides, Penicillins, Pleuromutilins, Polypeptides, Sulfas, Quinoxalines, and Streptogramins.

<sup>&</sup>lt;sup>1</sup> kg = kilogram of active ingredient. Antimicrobials which were reported in International Units (IU) (e.g., Penicillins) were converted to kg. Antimicrobial class includes drugs of different molecular weights, with some drugs reported in different salt forms.

<sup>&</sup>lt;sup>2</sup> Includes antimicrobial drug products which are approved and labeled for use in multiple species, including both food- and nonfood-producing animals, such as dogs and horses.

<sup>&</sup>lt;sup>3</sup> NIR = Not Independently Reported. Antimicrobial classes for which there were less than three distinct sponsors actively marketing products domestically were not independently reported. These classes include: Aminocoumarins, Amphenicols, Diaminopyrimidines, Fluoroquinolones, Glycolipids, Pleuromutilins, Polypeptides, Quinoxalines, and Streptogramins

### Table 2. Marketed Antimicrobial Drugs and Drug Classes Approved for Use inFood-Producing Animals

Aminocoumarins	Macrolides
Novobiocin	Erythromycin
	Gamithromycin
Aminoglycosides	Tilmicosin
Dihydrostreptomycin	Tulathromycin
Gentamicin	Tylosin
Neomycin	Penicillins
Spectinomycin	Amoxicillin
Streptomycin	Ampicillin
Amphenicols	Cloxacillin
Florfenicol	Penicillin
FIGHERICO	
Cephalosporins	Pleuromutilins
Ceftiofur	Tiamulin
Cephapirin	
	Polypeptides
Diaminopyrimidines	Bacitracin
Ormetoprim	
	Quinoxalines
Fluoroquinolones	Carbadox
Danofloxacin	
Enrofloxacin	Streptogramins
Ohan a Kasiala	Virginiamycin
Glycolipids	Sulfas
Bambermycins	Sulfadimethoxine
lonophores	Sulfamerazine
Laidlomycin	Sulfamethazine
Lasalocid	Sulfaquinoxaline
Monensin	
Narasin	Tetracyclines
Salinomycin	Chlortetracycline
	Oxytetracycline
Lincosamides	Tetracycline
Lincomycin	
Pirlimycin	